drugset / Trial / NCT01213979
Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.
Timeline
- Start
- 2012-02
- Primary completion
- 2012-05
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Iron isomaltoside 1000 | Unknown | 500 mg | Intravenous |
| Comparator | Iron isomaltoside 1000 | Unknown | 1000 mg | Intravenous |
Indications
No indication recorded.